All News

RA,Rx,puzzle

EULAR26: Pitfalls in Treat-to-Target

EurekAlert!

Real-world or observational data from registries, claims datasets, or electronic health records can enable us to perform large-scale analyses.

Read Article
Blood labs

2-Gene Blood Test for Kawasaki Disease in Febrile Children

Jack Cush, MD

JAMA Network Open has publshed that a simple 2-gene blood test may aid the earlier diagnosis of Kawasaki disease in children with febrile illnesses. 

Read Article
B CELL DEPLETION

B cell Targeting in SLE

MedPage Today

Prospects are growing that an approved, off-the-shelf drug can rescue patients with certain ultra-refractory autoimmune diseases, a pair of new reports suggest.

Read Article
pregnancy,embryo,fetal

No Fetal Risks with First Trimester NSAID Use

Jack Cush, MD

PLoS Medicine has published a population-based retrospective cohort study from the Southern Israeli Pregnancy Registry (siPREG) project showing that 1st trimester exposure to NSAIDs was not associated with major congenital malformatoin (MCM) risk. 

Read Article
Biomarker,genes

Where are we with Biomarkers in Rheumatoid Arthritis?

Jack Cush, MD

Biomarker interest has grown considerably in the last 2 decades, owing to advances in genetics, imaging, protein, and multiomics. Despite these advances, biomarkers as the predictive holy grail of RA therapeutics and prognostication have not yet advanced beyond rheumatoid serologies and C-reactive protein (CRP).

Read Article
SPA.spectrum.jpg

Redefining axial spondyloarthritis

Jack Cush, MD

An editorial in Lancet Rheumatology calls for "..reframing axSpA as a systemic, autoimmune inflammatory disease with multiorgan involvement and substantial unmet need."

Read Article
Steroids in SpA? DBRPCT of 94 (nonPsA) SpA pts w/ peripheral arthritis (SJC ≥ 2) placebo or steroids (GC) (csDMARDs background allowed). 76% male, age 32 yrs, TJC 10, SJC 3.6. Wk 24 there was no signif diff betw groups for ACR 50, ACR70 or PSpARC outcomes. https://t.co/snJovW31Uk
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 116 BL KOA (Kellgren–Lawrence I–II) pts rx w/ three PRP injx (n 58) or NSAIDs +/- IAhyaluronic acid (n 58). After 5 yrs there was no signif. difference in VAS, WOMAC, and SF-36, with both groups worsening. https://t.co/KDSMTvEl59 https://t.co/lgHOsppIU3

Links:

Dr. John Cush RheumNow ( View Tweet)
Mentors & Mentees can do great things!!! https://t.co/gdf5laCuCm

Links:

Dr. John Cush RheumNow ( View Tweet)

Chinese study of 341 RA pts, half managed post D/C w/ nurse led AI interactive platform vs usual care. @ 6 mos AI platform group had signif better outcomes - DAS28 (-0.77 vs -0.27), HAQ functional status, medication adherence (90 vs 80%), and pt satisfaction (96 vs 76%) https://t.co/SrDgUuAWB3
Dr. John Cush RheumNow ( View Tweet)
Korean insurance claims study of 50 600 adults w/ newly dx #RA - Persistent low-income significantly increased mortality risk, especially if RA <65 yrs or rural residence; Sustained high-income status provided a protective effect across all age group https://t.co/OIhvz489Ar https://t.co/lYwgc2Ty3n

Links:

Dr. John Cush RheumNow ( View Tweet)
JAMA Review on Low Back Pain A comprehensive JAMA review synthesizes current evidence on the epidemiology, pathophysiology, clinical evaluation, and treatment of nonspecific low back pain (nsLBP), drawing on 108 publications identified from a PubMed search (2005–2026) and the https://t.co/liEitQ2ACf
Dr. John Cush RheumNow ( View Tweet)
Can AI Predict Progression to RA? Dr. Jonathan Kay reports on abstract POS0967 at EULAR 2026 in London https://t.co/m8wvp93mTA https://t.co/ADZa9C4068

Links:

Dr. John Cush RheumNow ( View Tweet)
Do You Zoster Vaccinate? (6.19.2026) Dr. Jack Cush reviews the news, journal reports and best ways to review EULAR 2026. https://t.co/hOfXR39s3H https://t.co/X7skwKrCc3

Links:

Dr. John Cush RheumNow ( View Tweet)
Missed a session at EULAR 2026? No problem. The RheumNow Faculty Reporter team was on the ground covering the studies, debates, and breakthroughs that are shaping the future of rheumatology. From JAK safety and CAR-T therapies to advances in lupus, psoriatic arthritis, and ILD, https://t.co/YZ7oRNXfqU
Dr. John Cush RheumNow ( View Tweet)
Type 2 diabetes pts taking semaglutide have a 15% lower risk of fractures. Endocrine society abstract EHR study of 26K SEM vs controls. Previous studies have linked rapid weight loss to a greater risk of fractures https://t.co/7nRYST5fPX https://t.co/kJ9Y5gcXFD https://t.co/AD6iVfkK3w

Links:

Dr. John Cush RheumNow ( View Tweet)
Prospective study of 6 newly Dx RA pts starting MTX shows MTX causes a decline in T follicular helper (Tfh) cells and plasmablasts (@ wk 3 before clin response), selectively in responders but not nonresponders. MTX shifts cellular & gene expression towards a more physiological https://t.co/Q1M4vgN0aD
Dr. John Cush RheumNow ( View Tweet)
#TB Infection or reactivation is Psoriasis or Psoriatic Arthritis pts taking IL-23 inhibitors is rare, rare. Literature review showed 34 studies of IL-23i in PsO had no new TB, but 1 case of LTBI reactivation. In 8 IL-23i PsA studies there were NO new TB or LTBI reactivations https://t.co/NFIap7DSOr
Dr. John Cush RheumNow ( View Tweet)
Systematic review of live virus MMR in #JIA had 9 studies (743 pts) showing no flares, good safety & immunogenicity in short term, BUT incomplete or less durable protection in biologic-treated patients, especially for measles & rubella. 5-yrs post MMR, seroprotection was lower if https://t.co/JQhL9o1O4e
Dr. John Cush RheumNow ( View Tweet)
EULAR 2026: Updated Recommendations for Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases The 2026 EULAR vaccination recommendations, presented by Victoria Furer, were developed by a multinational 25-member task force that include rheumatologists, an https://t.co/AFnsmEYj41
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×